09/04/2026
๐ ๐ผ๐๐ ๐ฒ๐
๐ฝ๐ผ๐ฟ๐ ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น ๐๐ถ๐ผ๐น๐ฎ๐๐ถ๐ผ๐ป๐ ๐ฑ๐ผ๐ปโ๐ ๐๐๐ฎ๐ฟ๐ ๐๐ถ๐๐ต ๐ฟ๐ฒ๐ฐ๐ธ๐น๐ฒ๐๐ ๐ถ๐ป๐๐ฒ๐ป๐.
They start with a classification that was accurate in 2024 and never revisited.
Delegated Regulation (EU) 2025/2003 entered into force across all 27 EU Member States simultaneously. No grace period. No phased rollout.
Products in quantum computing, semiconductor manufacturing, additive manufacturing and biotech moved into materially different licensing territory.
Here's what makes this update different from routine list maintenance:
โ For the first time, the EU added controls outside multilateral consensus, the new "500 series" is the EU acting on its own security assessment, not waiting for Wassenaar.
โ The catch-all clause (Article 4, Regulation (EU) 2021/821) is being actively enforced, not just for listed goods, but for intangibles: cloud access, technical data, research collaborations.
โ Pre-November 2025 classification assessments are no longer reliable in affected sectors. Full stop.
The businesses most at risk right now aren't the ones exporting missiles. They're the ones that have not reviewed their product portfolios since the list changed, and assume that because nothing has happened yet, everything is fine.
Tightened controls across four principal areas:
Quantum technology: Strengthened parameters covering computers, cryogenic cooling systems, quantum key distribution components, parametric signal amplifiers and cryogenic wafer probers. Priority review area for any organisation with non-EU research or commercial partners.
Semiconductor manufacturing equipment: Thresholds revised downward across ALD systems, lithography tools, EUV pellicles, etching equipment and scanning electron microscopes. The practical burden falls hardest on European manufacturers supplying Asian markets and distributors handling second-hand fabrication assets.
Additive manufacturing: Controls extended beyond metal powder bed fusion hardware to capture related software, metal powder inoculants and high-performance alloys with proliferation-relevant specifications.
Biotechnology: Gene and peptide synthesis equipment controls amended to reflect accelerated dual-use risks associated with synthetic biology and post-pandemic technology development.
If your company touches quantum hardware, chips, 3D-printing materials, or life sciences tools, and you have any non-EU supply chain, research partners or customer base, this is not a compliance formality. It's a live legal exposure.
Read more https://orugagroup.com/en/insights/eu-dual-use-export-controls-in-2026.html
hashtag hashtag hashtag hashtag hashtag hashtag
